Marinus Pharmaceuticals Inc (MRNS.OQ)
22 Jan 2018
Wed, Nov 1 2017
* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing Source text: [http://bit.ly/2z23P1a] Further company coverage:
* Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results
* Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2fUP6u2) Further company coverage:
* Marinus Pharmaceuticals announces pricing of public offering of common stock
* Marinus Pharmaceuticals Inc announces public offering of common stock
* Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone
* EecoR1 Capital LLC report a 12.2 percent passive stake in Marinus Pharmaceuticals Inc as of August 4, 2017 - SEC filing Source text: (http://bit.ly/2vMhmJe) Further company coverage:
* Provides business update and reports second quarter 2017 financial results
- Marinus Pharma's Ganaxolone: If At First You Don't Succeed...
- 2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?
- Marketplace Authors' Top Picks For 2018
- Biotech: The Tide Is Turning
- Healthcare Biotech Sector Breakout: How High Will It Go In 2018?
- Will Marinus Pharmaceuticals Come Crashing Down In 2018?